3
Announcements
Trials
Browse
Landscape
Phase
Phase NA
1
Status
Not yet recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Myeloid
1
Conditions
Motor Activity
9
Neoplasms
4
Prostatic Neoplasms
3
Pancreatic Neoplasms
3
Obesity
3
Colorectal Neoplasms
3
Breast Neoplasms
3
Brain Neoplasms
3
Sarcopenia
2
Multiple Myeloma
2
Weight Loss
1
Triple Negative Breast Neoplasms
1
Thrombocythemia, Essential
1
Smoldering Multiple Myeloma
1
Skin Neoplasms
1
Renal Insufficiency, Chronic
1
Rehabilitation Exercise
1
Primary Myelofibrosis
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Polycythemia Vera
1
Overweight
1
Neoplasms, Plasma Cell
1
Myeloproliferative Disorders
1
Melanoma
1
Lymphoma, B-Cell
1
Lymphoma
1
Lymphedema
1
Lung Neoplasms
1
Locally Advanced Head and Neck Squamous Cell Carcinoma
1
Leukemia, Myeloid, Acute
1
Interventions
Cyclophosphamide
29
fludarabine phosphate
22
Whole-Body Irradiation
20
Mycophenolic Acid
20
fludarabine
19
asciminib
19
nilotinib
16
Tacrolimus
13
Imatinib Mesylate
13
Melphalan
11
Dasatinib
9
Sirolimus
8
Peripheral Blood Stem Cell Transplantation
8
Thiotepa
7
Granulocyte Colony-Stimulating Factor
7
Busulfan
7
bosutinib
6
Mesna
6
Cyclosporine
6
ponatinib
5
Stem Cell Transplantation
5
Filgrastim
5
venetoclax
4
ruxolitinib
4
blinatumomab
4
Specimen Handling
4
Cyclosporins
4
thymoglobulin
3
Bone Marrow Transplantation
3
Antilymphocyte Serum
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
×
Resistance Training
×
1 year
×
Clear all
NCT07518940
2026-04-09
ENERGIA
University of Turin, Italy
Phase NA
Not yet recruiting
25 enrolled